Abstract
Purpose. Stachyflin and its derivatives which are active against the influenza virus in vitro, were studied to improve their reduced in vivo activity after oral administration by chemical modification and some vehicles.
Methods. The solubility was examined for different vehicles. The improvement of gastrointestinal absorption was evaluated by the plasma concentration after oral administration to mice or the in situ loop method with rats. The in vivo anti-influenza activity was examined using mice infected with the influenza virus and evaluated based on the virus titer in the lung by TCID50.
Results. PEG 400 showed the highest solubility of Stachyflin and its derivative among the vehicles studied. While no viral inhibition was found in the lung after oral administration of 0.5% HPMC suspension of Stachyflin, in vivo anti-influenza virus activity was found with the PEG 400 solution. The absorption of Stachyflin by PEG 400 showed about a fifty-fold increase in AUC compared with that of 0.5% HPMC suspension. Improving the oral absorption of Stachyflin led to an increase in the in vivo anti-influenza virus activity. When the Stachyflin derivative in PEG 4000 was administered orally, there was more enhancement of the oral absorption than with PEG 400. When the aqueous solution of the phosphate ester prodrugs of Stachyflin and its derivative was administered orally, the absorption of the parent compound was improved and in vivo anti-influenza virus activity was found.
Conclusions. When Stachyflin and its derivatives were administered orally to mice with a solution in PEG and an aqueous solution of their phosphate ester, their oral absorption was improved and in vivo anti-influenza virus activity was observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
T. Taishi, S. Takechi, and S. Mori. First total synthesis of (±)-Stachyflin. Tetrahedron Lett. 39:4347–4350 (1998).
J. Yoshimoto, N. Hattori, M. Kakui, H. Iwasaki, H. Sugimoto, and T. Fujiwara. Identification of a phenotypically irreversible HA conformational change inhibitor. Arch. Virol. (in press).
L. H. Pinto, L. J. Holsinger, and R. A. Lamb. Influenza virus M2 protein has ion channel activity. Cell 69:517–528 (1992).
C. Schroeder, C.-M. Ford, S.-A. Wharton, and A. J. Hay. Functional reconstitution in lipid vesicles of influenza virus M2 protein expressed by baculovirus: Evidence for proton transfer activity. J. Gen. Viol. 75:3477–3484 (1994).
R. J. Sugrue and A. J. Hay. Structural characteristics of the M2 protein of influenza A viruses: Evidence that it forms a tetrameric channel. Virology 180:617–624 (1991).
A. J. Hay. Potential targets and actions of antiviral agents against influenza viruses. Chem. Scr. 26:77–81 (1986).
A. J. Hay. The action of adamantamines against influenza a viruses: inhibition of the M2 ion channel protein. Semin. Virol. 3:21–30 (1992).
R. M. Atkinson, C. Bedford, K. J. Child, and E. G. Tomich. Effect of particle size on blood griseofulvin-levels in man. Nature 193:588–589 (1962).
K. B. Choudhari and N. M. Sanghavi. Dissolution behavior and characterization of diazepam-pullulan coground mixtures. Int. J. Pharm. 89:207–211 (1993).
A. B. Straughn, M. C. Meyer, G. Raghow, and K. Potenberg. Bioavailability of microsize and ultramicrosize griseofulvin products in man. J. Pharmacokinet. Biopharm. 8:347–362 (1980).
W. E. Barrett and J. R. Bianche. The bioavailavility of ultramicrosize griseofulvin (GRIS-PEG) tablets in man. Curr. Ther. Res. 18:501–509 (1980).
J. H. Fincher. Particle-size of drugs and its relationship to absorption and activity. J. Pharm. Sci. 57:1825–1835 (1968).
F. Nimmerfall and J. Rosenthaler. Dependence area under the curve on proquazone particle size and in vitro dissolution rate. J. Pharm. Sci. 69:605–607 (1980).
H. E. Paul, K. J. Hayes, M. F. Paul, and A. R. Borgmann. Laboratory studies with nitrofurantoin. J. Pharm. Sci. 56:882–885 (1967).
A. S. Ridolfo, L. Thompkins, L. D. Bechtol, and R. H. Carmichael. Benoxaprofen, a new anti-inflammatory agent: particle size effect on dissolution rate and oral absorption in humans. J. Pharm. Sci. 68:850–852 (1979).
S-L Lin, J. Menig, and L. Lachman. Interdependence of physiological surfactant and drug particle size on the dissolution behavior of water-insoluble drugs. J. Pharm Sci. 57:2413–2148 (1968).
R. L. Oberle and T. L. Moore. Evaluation of nonionic surfactants to improve solubility and oral absorption of CGS-9896. Pharm. Res. 10:Suppl., S222 (1993).
A. B. Straughn, M. C. Mayer, G. Raghow, and K. Rotenberg. Bioavailability of microsize and ultramicrosize griseofuluvin products in man. J. Pharmacokin. Biopharm. 8:347–362 (1980).
I. Sugimoto, A. Kuchiki, H. Nakagawa, K. Togo, S. Kondo, I. Iwane, and K. Takahashi. Dissolution and absorption of nifedipine from nifedipine-polyvinylpyrrolidone coprecipitate. Drug Der. Ind. Pharm. 6:137–160 (1980).
N. Hashimoto, T. Fujioka, K. Hayashi, K. Odaguchi, T. Toyoda, M. Nakayama, and K. Hirano. Renin inhibitor: Relationship between molecular structure and oral absorption. Pharm. Res. 11:1443–1447 (1994).
S. A. Varia and V. J. Stella. Phenytoin prodrugs V: In vivo evaluation of some water-soluble phenytoin prodrugs in dogs. J. Pharm. Sci. 73:1080–1087 (1984).
S. A. Varia and V. J. Stella. Phenytoin prodrugs VI: In vivo evaluation of a phosphate ester prodrug of phenytoin after parenteral administration to rats. J. Pharm. Sci. 73:1087–1090 (1984).
D. Fleisher, K. C. Johnson, B. H. Stewart, and G. L. Amidon. Oral absorption of 21-corticosteroid esters: A function of aqueous stability and intestinal enzyme activity and distribution. J. Pharm. Sci. 75:934–939 (1986).
C. Sessa, M. Zucchetti, T. Cerny, O. Pagani, F. Cavalli, M. De Jong, D. Gentili, C. McDaniel, C. Prins, L. Schacter, B. Winograd, and M. D'Incalci. Phase I clinical and pharmacokinetic study of oral etoposide phosphate. J. Clin. Oncol. 13:200–209 (1995).
N. Muranushi, T. Yoshikawa, M. Nishiuchi, T. Oguma, K. Hirano, and H. Yamada. Characteristics of the intestinal absorption of 7432-S, a new orally active cephalosporin. 18th Symposium on Drug Metabolism and Action. Abstr. 55–58 (1986).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yagi, S., Ono, J., Yoshimoto, J. et al. Development of Anti-Influenza Virus Drugs I: Improvement of Oral Absorption and In Vivo Anti-Influenza Activity of Stachyflin and Its Derivatives. Pharm Res 16, 1041–1046 (1999). https://doi.org/10.1023/A:1018983715982
Issue Date:
DOI: https://doi.org/10.1023/A:1018983715982